Skip to content

US · BTAI · BIOTECHNOLOGY

BioXcel Therapeutics, Inc. (BTAI) intrinsic value and stock valuation

$0.07as of 2026-11-21 · Mkt cap 25.96M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BioXcel Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values BTAI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BTAI’s statements →

BioXcel Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New Haven, CT 06511 bioxceltherapeutics.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$640K
20152025
Net income
-$-69.9M
20152025
Free cash flow
-$-57.62M
20152025
Total equity
-$-95.46M
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$640K$2.27M$1.38M$380K$0.00
Operating income-$-50.27M-$-67.25M-$-171.78M-$-159.65M-$-106.94M
Net income-$-69.9M-$-59.6M-$-179.05M-$-165.76M-$-106.93M
EPSd-$-5.72M-$-23.46M-$-98.38M-$-94.72M-$-64.81M
Operating cash flow-$-57.62M-$-72.03M-$-155.01M-$-135.34M-$-82.15M
Capital expenditure$0.00$0.00-$-20K-$-140K-$-450K
Free cash flow-$-57.62M-$-72.03M-$-155.03M-$-135.48M-$-82.6M
Total assets$44.9M$38.3M$73.7M$205.9M$239.4M
Total debt$109.7M$103M$101.4M$94.2M$1.4M
Net debt$81.2M$73.1M$36.2M-$-99.57M-$-231.57M
Total equity-$-95.46M-$-93.1M-$-56.51M$76.8M$221.7M
Cash and short-term investments$28.4M$29.9M$65.2M$193.7M$233M
Income statement
20252024202320222021
Revenue$640K$2.27M$1.38M$380K$0.00
Cost of revenue$160K$2.14M$1.26M$20K$0.00
Gross profit$480K$120K$120K$350K$0.00
Research and development expenses$30.3M$30.4M$84.3M$91.2M$52.7M
Selling, general and administrative expenses$20.5M$34.5M$83.4M$68.8M$54.2M
Other expenses$0.00$2.44M$4.16M$0.00-$0.00
Operating expenses$50.7M$67.4M$171.9M$160M$106.9M
Cost and expenses$50.9M$69.5M$173.2M$160M$106.9M
Interest income$1.07M$2.6M$5.65M$2.53M$0.00
Interest expense$17M$15.1M$13.3M$8.21M$40K
Depreciation and amortization$300K$310K$320K$330K$300K
Ebitda-$-52.61M-$-44.16M-$-165.42M-$-157.22M-$-106.59M
Operating income-$-50.27M-$-67.25M-$-171.78M-$-159.65M-$-106.94M
Total other income/expenses, net-$-19.63M$7.65M-$-7.27M-$-6.11M$0.00
Income before tax-$-69.9M-$-59.6M-$-179.05M-$-165.76M-$-106.93M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-69.9M-$-59.6M-$-179.05M-$-165.76M-$-106.93M
Weighted average shares outstanding$12.2M$2.54M$1.82M$1.75M$1.65M
Weighted average diluted shares outstanding$12.2M$2.54M$1.82M$1.75M$1.65M
Balance sheet
20252024202320222021
Cash and short-term investments$28.4M$29.9M$65.2M$193.7M$233M
Net receivables$230K$130K$70K$250K$0.00
Inventory$720K$680K$1.99M$1.99M$0.00
Total current assets$44.7M$37.4M$72.1M$202.9M$236.8M
Property, plant and equipment, net$230K$860K$1.47M$2.06M$2.54M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$230K$940K$1.56M$2.98M$2.63M
Total assets$44.9M$38.3M$73.7M$205.9M$239.4M
Accounts payable$14.7M$16M$13.7M$10.2M$4.68M
Short-term debt$25M$370K$350K$320K$290K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$53.9M$22.2M$27.3M$32.9M$16.7M
Long-term debt$84.7M$102.6M$101M$93.8M$1.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$86.5M$109.2M$102.9M$96.2M$1.1M
Capital lease obligations$70K$440K$790K$1.1M$1.4M
Total liabilities$140.4M$131.4M$130.2M$129.1M$17.8M
Common stock$80K$50K$30K$30K$30K
Retained earnings-$-720.09M-$-650.2M-$-590.6M-$-411.55M-$-245.79M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-95.46M-$-93.1M-$-56.51M$76.8M$221.7M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$109.7M$103M$101.4M$94.2M$1.4M
Net debt$81.2M$73.1M$36.2M-$-99.57M-$-231.57M
Cash flow statement
20252024202320222021
Net income-$-69.9M-$-59.6M-$-179.05M-$-165.76M-$-106.93M
Depreciation and amortization$300K$310K$320K$330K$300K
Stock-based compensation$2.77M$6.16M$18.6M$17.3M$19.5M
Change in working capital-$-1.7M-$-6.03M$2.02M$10.4M$4.98M
Accounts receivable-$-100K-$-60K$180K-$-250K$0.00
Inventory-$-40K$1.31M-$-10K-$-1.99M$0.00
Accounts payable$6.97M-$-4.33M-$-3.22M$13M$4.85M
Net cash provided by operating activities-$-57.62M-$-72.03M-$-155.01M-$-135.34M-$-82.15M
Investments in property, plant and equipment$0.00$0.00-$-20K-$-140K-$-450K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00-$-20K-$-140K-$-450K
Common stock issued$56.5M$39.7M$27M$280K$101M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$56.5M$36.7M$26.5M$96.2M$102.5M
Net change in cash-$-1.1M-$-35.37M-$-128.5M-$-39.24M$19.9M
Cash at end of period$28.8M$29.9M$65.2M$193.7M$233M
Operating cash flow-$-57.62M-$-72.03M-$-155.01M-$-135.34M-$-82.15M
Capital expenditure$0.00$0.00-$-20K-$-140K-$-450K
Free cash flow-$-57.62M-$-72.03M-$-155.03M-$-135.48M-$-82.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BioXcel Therapeutics, Inc.

        BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder. Beyond its current commercial use, BXCL501 is also undergoing further clinical investigation. Studies are underway to assess its efficacy for agitation in individuals with Alzheimer's disease, as an add-on therapy for major depressive disorder, and for use in community settings to address agitation linked to bipolar disorders and schizophrenia. Furthermore, BioXcel is advancing BXCL502, a candidate therapy targeting chronic agitation prevalent in dementia patients. Another key pipeline asset is BXCL701, an orally administered systemic innate immunity activator currently under investigation. This compound shows promise for treating aggressive prostate cancer and advanced solid tumors that have either become resistant to checkpoint inhibitors or have not yet received such treatment. Established in 2017, the company maintains its headquarters in New Haven, Connecticut.

        CEO
        Vimal D. Mehta
        Employees
        29
        Beta
        0.27

        Explore

        Frequently asked questions

        What is the intrinsic value of BioXcel Therapeutics, Inc. (BTAI)?

        InvestorsCraft does not currently publish an intrinsic value for BTAI. How the IC value is calculated.

        Is BTAI undervalued?

        InvestorsCraft does not publish an undervaluation signal for BTAI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.